Restaging transurethral resection (re-TUR) of high grade T1 bladder cancer (HGT1-BC) is recommended but the impact in terms of recurrence-free survival (RFS) and progression-free survival (PFS) is discussed. The objective of this study was to evaluate our practice of re-TUR for these tumors and its impact on overall survival (OS), RFS and PFS.
A retrospective observational study was conducted between 2010 and 2020. The inclusion criteria was the presence of newly diagnosed HGT1-BC. Patients with incomplete resection, suspicion of infiltrating tumor, upper tract urothelial cancer, or metastatic disease were ineligible. Two groups were defined : Group 1 with re-TUR and Group 2 without re-TUR. RFS and PFS were evaluated.
A total of 78 patients were included, including 50 (64,1%) in group 1. There were no significant differences between the two groups. The mean time to re-TUR was 8 weeks and 60% residual tumor was found. Initial under-staging was found in 12% of cases. RFS and PFS were significantly better in Group 1 (P=0.0019; P=0,02). No significant were found between the groups in OS and specific survival (SS).
Performing a re-TUR for high grade T1 bladder tumors allows detection of residual tumor and decreases the risk of under-evaluation. It is associated with a significant improvement in RFS and PFS with no impact on OS and SS.
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2023 Jan 03 [Epub ahead of print]
A Brun, N Koutlidis, T Thibault, A Escoffier, F Bardet, L Cormier
Service d'urologie et andrologie, centre hospitalier universitaire François-Mitterrand, Dijon, France; Service d'urologie, centre hospitalier William Morey, Chalon sur Saône, France. Electronic address: ., Service d'urologie, centre hospitalier William Morey, Chalon sur Saône, France., Service de médecine interne, centre hospitalier universitaire Francois-Mitterrand, Dijon, France., Service d'urologie et andrologie, centre hospitalier universitaire François-Mitterrand, Dijon, France.